Though the opposing antitumor activities of IFN-γ seem contradictory at first glance, this opens avenues to set up effective combination therapies of cancer vaccines with anti-PD-1/PD-L1 therapy, as demonstrated in several clinical trials 19,20. This evidence concerns the gene CD274 and cancer.